In this analysis, we investigated utilization patterns of alosetron and eluxadoline. Two patient cohorts assessed these products without inclusion or exclusion requirements. Two additional cohorts assess these products with an inclusion requirement of a diagnosis of irritable bowel syndrome (IBS) in addition to an exclusion requirement of a diagnosis of intestinal ischemia.
The study period includes data from January 1, 2010 to September 30, 2020.
We executed this request on Merative™ MarketScan® Research Databases on August 17, 2021.